RNA primers and the role of host nuclear RNA polymerase II in influenza viral RNA transcription.
Influenza viral RNA transcription in the infected cell is inhibited by alpha-amanitin, a specific inhibitor of the host nuclear RNA polymerase II. Because viral RNA transcription in vitro catalysed by the virion-associated transcriptase is greatly enhanced by the addition of a primer dinucleotide, ApG or GpG, we have proposed that viral RNA transcription in vivo requires initiation by primer RNAs synthesized by RNA polymerase II. In addition, because we did not detect any capping and methylating enzymes in virions, we have proposed that the 5' terminal methylated cap found on in-vivo viral messenger RNA (mRNA) is derived from the putative primer RNAs. Our recent experiments have proved these two hypotheses. Purified globin mRNAs were shown to stimulate viral RNA transcription in vitro very effectively. The resulting transcripts directed the synthesis of all the non-glycosylated virus-specific proteins in cell-free systems. Other eukaryotic mRNAs were also active as primers. The presence of a 5' terminal methylated cap structure in the priming mRNA was required for its priming activity. Thus, with globin mRNA, removal of the cap eliminated essentially all of its priming activity, and much of this activity could be restored by enzymically recapping the globin mRNA. Using globin mRNA containing 32P only in its cap, we demonstrated that the 5' cap of the globin mRNA primer was physically transferred to the viral RNA transcripts during transcription. Gel electrophoretic analysis suggested that, in addition to the cap, about 10-15 other nucleotides were also transferred from the globin mRNA to the viral RNA transcripts. A mechanism for the priming of influenza viral RNA transcription by globin mRNA is proposed. Initial experiments strongly suggest that priming by capped host mRNAs also occurs during the synthesis of viral mRNA in vivo.
D000546:Amanitins / Q000494:pharmacology; D002467:Cell Nucleus / Q000201:enzymology; D002474:Cell-Free System; D012321:DNA-Directed RNA Polymerases / Q000378:metabolism*; D005914:Globins / Q000235:genetics; D009694:Nucleic Acid Precursors / Q000378:metabolism; D009975:Orthomyxoviridae / Q000235:genetics*; D012315:RNA Caps / Q000378:metabolism; D012319:RNA Polymerase II / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D012367:RNA, Viral / Q000096:biosynthesis*; D014158:Transcription, Genetic / Q000187:drug effects; D014779:Virus Replication
D000546:Amanitins; D009694:Nucleic Acid Precursors; D012315:RNA Caps; D012333:RNA, Messenger; D012367:RNA, Viral; D005914:Globins; D012319:RNA Polymerase II; D012321:DNA-Directed RNA Polymerases